Philippe DUCHATEAU,Jean-Pierre CABANIOLS,Julien VALTON
申请号：
US15578946
公开号：
US20180171298A1
申请日:
2016.06.30
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention relates to methods for improving therapeutic activity of NK cell, such as their cytotoxic/cytolytic activity, to be used in immunotherapy, by gene editing. In particular, these methods comprise a step of reduction or inactivation of gene expression using specific endonuclease such as TAL-nuclease, CRISPR or Argonaute. An additional genetic modification can be performed by (over)expressing at least one gene involved in N K function. The present invention encompasses also engineered NK cell, pharmaceutical composition containing the same.
